Comparison of the effects of sibutramine and orlistat on obese, poorly-controlled type 2 diabetic patients

Chang Gung Medical Journal

Volumn 30, Issue 6, 2007, Pages 538-546

  Chou, Kuei Mei ^a   Huang, Be Yi ^a   Fanchiang, Jen Kuang ^a   Chen, Chih Hung ^a,b  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Obesity; Orlistat; Sibutramine; Type 2 diabetes mellitus; Weight reduction

Indexed keywords

CHOLESTEROL; FENOFIBRATE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BILE LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

ADULT; AGED; ANTI-OBESITY AGENTS; BLOOD GLUCOSE; CHOLESTEROL, LDL; CROSS-OVER STUDIES; CYCLOBUTANES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; LACTONES; MALE; MIDDLE AGED; OBESITY; PROSPECTIVE STUDIES; WEIGHT LOSS;

EID: 38549139693     PISSN: 02558270     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Curran MP, Scott LJ. Orlistat: a review of its use in the management of patients with obesity. Drugs 2004;64:2845-64.
2. Scheen AJ. Current management strategies for coexisting diabetes mellitus and obesity. Drugs 2003;63:1165-84.
3. Galloway JA. Treatment of NIDDM with insulin agonists or substitutes. Diabetes Care 1990;13:1209-39.
4. Genuth S. Insulin use in NIDDM. Diabetes Care 1990;13:1240-64.
5. Hollander P. Orlistat in the treatment of obesity. Prim Care 2003;30:427-40.
6. Nisoli E, Carruba MO. A benefit-risk assessment of sibutramine in the management of obesity. Drug Saf 2003;26:1027-48.
7. Abraham WT. Preventing cardiovascular events in patients with diabetes mellitus. Am J Med 2004;116:39S-46S.
8. Scheen AJ, Lefebvre PJ. Antiobesity pharmacotherapy in the management of type 2 diabetes. Diabetes Metab Res Rev 2000;16:114-24.
9. Tong PC, Lee ZS, Sea MM, Chow CC, Ko GT, Chan WB, So WY, Ma RC, Ozaki R, Woo J, Cockram CS, Chan JC. The effect of orlistat-induced weight loss, without concomitant hypocaloric diet, on cardiovascular risk factors and insulin sensitivity in young obese Chinese subjects with or without type 2 diabetes. Arch Intern Med 2002;162:2428-35.
10. Snider LJ, Malone M. Orlistat use in type 2 diabetes. Ann Pharmacother 2002;36:1210-8.
11. Hung YJ, Chen YC, Pei D, Kuo SW, Hsieh CH, Wu LY, He CT, Lee CH, Fan SC, Sheu WH. Sibutramine improves insulin sensitivity without alteration of serum adiponectin in obese subjects with type 2 diabetes. Diabet Med 2005;22:1024-30.
12. Arterburn DE, Crane PK, Veenstra DL. The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Intern Med 2004;164:994-1003.
13. Ryan DH. Use of sibutramine to treat obesity. Prim Care 2003;30:405-26.
14. Scheen AJ, Ernest P. New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat. Diabetes Metab 2002;28:437-45.
15. Albu J, Raja-Khan N. The management of the obese diabetic patient. Prim Care 2003;30:465-91.
16. Grizzle JE. The two-period change-over design and its use in clinical trials. Biometrics 1965;21:467-80.
17. Vettor R, Serra R, Fabris R, Pagano C, Federspil G. Effect of sibutramine on weight management and metabolic control in type 2 diabetes: a meta-analysis of clinical studies. Diabetes Care 2005;28:942-9.
18. Fujioka K, Seaton TB, Rowe E, Jelinek CA, Raskin P, Lebovitz HE, Weinstein SP; Sibutramine/Diabetes Clinical Study Group. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diabetes Obes Metab 2000;2:175-87.
19. Bray GA, Blackburn GL, Ferguson JM, Greenway FL, Jain AK, Mendel CM, Mendels J, Ryan DH, Schwartz SL, Scheinbaum ML, Seaton TB. Sibutramine produces dose-related weight loss. Obes Res 1999;7:189-98.
20. McMahon FG, Weinstein SP, Rowe E, Ernst KR, Johnson F, Fujioka K; Sibutramine in Hypertensives Clinical Study Group. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. J Hum Hypertens 2002;16:5-11.
21. Hanotin C, Thomas F, Jones SP, Leutenegger E, Drouin P. Efficacy and tolerability of sibutramine in obese patients: a dose-ranging study. Int J Obes Relat Metab Disord 1998;22:32-8.
22. McNeely W, Benfield P. Orlistat. Drugs 1998;56:241-9.
23. Sjostrom L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP, Krempf M. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 1998;352:167-72.
24. Reaven G, Segal K, Hauptman J, Boldrin M, Lucas C. Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X. Am J Cardiol 2001;87:827-31.